Viracta Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Viracta Therapeutics has a total shareholder equity of $18.3M and total debt of $25.3M, which brings its debt-to-equity ratio to 138%. Its total assets and total liabilities are $56.7M and $38.4M respectively.
Key information
138.0%
Debt to equity ratio
US$25.27m
Debt
| Interest coverage ratio | n/a |
| Cash | US$53.83m |
| Equity | US$18.32m |
| Total liabilities | US$38.37m |
| Total assets | US$56.69m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: VIRX's short term assets ($55.0M) exceed its short term liabilities ($38.4M).
Long Term Liabilities: VIRX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: VIRX has more cash than its total debt.
Reducing Debt: VIRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VIRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VIRX has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 30.4% each year.